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The induction, execution, and maintenance of 
immune tolerance requires direct cell–cell contact 
mediated by specifi  c surface molecules on APCs, 
notably MHC-II, B7.1, B7.2, and ICOSL, and 
their corresponding partners on T lymphocytes 
(1–5). As these molecules are also involved in 
T cell activation, it is unclear how APCs function 
to facilitate both immune tolerance and activation. 
One potential mechanism that controls such 
opposite eff  ects is the current dogma on APC 
maturation status, which is that immature DCs 
and nonprofessional APCs that lack suffi   cient 
surface expression of costimulatory molecules 
induce T cell apoptosis, anergy, or diff  erentiation 
of suppressor T cells, whereas mature DCs that 
express high levels of costimulatory molecules 
support immune activation (2).
Another mechanism by which APCs control 
immune activation versus suppression involves 
their ability to modulate the production of pro- 
(IL-6, GM-CSF, and IFN-γ) and antiinfl  am-
matory cytokines (IL-10 and TGF-β) (1, 6–8). 
In particular, it was recently reported that IL-6, 
together with TGF-β, promotes the generation 
of Th17 cells, which are a distinct T cell lineage 
characterized by their ability to produce large 
quantities of  IL-17 (9, 10). Interestingly, despite the 
abundant expression of costimulatory molecules 
such as CD80 and CD40, certain diff  erentiated 
DCs are fully capable of suppressing T cell activa-
tion (7, 11). Thus, the mechanism that dictates 
the ability of APCs to induce immune activation 
versus immune tolerance cannot be explained 
only by the levels of costimulatory molecules.
One of the highly expressed molecules on 
APCs is integrin CD11b/CD18 (αM, Mac-1, 
and CR3). Based on the observation that C3bi, 
which is a specifi  c ligand of CD11b/CD18 (12), 
functions critically in the development of spe-
cifi  c forms of immune suppression (13, 14), we 
hypo  thesize that the development of peripheral 
immune tolerance is dependent on CD11b/
CD18. In this study, we tested the role of CD11b 
in orally induced peripheral immune tolerance 
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Antigen-induced immune suppression, like T cell activation, requires antigen-presenting 
cells (APCs); however, the role of APCs in mediating these opposing effects is not well 
understood, especially in vivo. We report that genetic inactivation of CD11b, which is a 
CD18 subfamily of integrin receptors that is highly expressed on APCs, abolishes orally 
induced peripheral immune tolerance (oral tolerance) without compromising APC matura-
tion or antigen-specifi  c immune activation. The defective oral tolerance in CD11b−/− mice 
can be restored by adoptive transfer of wild-type APCs. CD11b defi  ciency leads to enhanced 
interleukin (IL) 6 production by APCs, which subsequently promotes preferential differen-
tiation of naive T cells to T helper 17 (Th17) cells, which are a T cell lineage characterized 
by their production of IL-17. Consequently, antigen feeding and immunization of CD11b−/− 
mice results in signifi  cant production of IL-17 within the draining lymph nodes that inter-
feres with the establishment of oral tolerance. Together, we conclude that CD11b facilitates 
oral tolerance by suppressing Th17 immune differentiation.
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(oral tolerance) using CD11b−/− mice. Our data show that 
genetic inactivation of CD11b does not signifi  cantly aff  ect the 
maturation of APCs or the cellular compositions of the draining 
LNs. Rather, CD11b defi  ciency leads to increased expression 
of IL-6, preferential immune deviation toward the Th17 path-
way, and enhanced production of IL-17, which in  terferes 
with the establishment of oral tolerance. Together, this study 
identifi  es CD11b/CD18 as an important player in the devel-
opment of antigen-induced immune tolerance, at least in part 
because of its ability to suppress Th17 diff  erentiation.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
CD11b−/− mice exhibit defective antigen-induced 
oral tolerance
Recent studies demonstrate that unlike its homologue recep-
tor CD11a, genetic inactivation of CD11b does not protect 
mice from the development of autoimmune diseases. On the 
contrary, CD11b defi  ciency worsens the infl  ammation and 
disease progression in several autoimmune disease models, 
including systemic lupus erythematosus, asthma, and arthritis 
(15–17), suggesting that CD11b/CD18 is potentially involved 
in immune suppression rather than immune activation. To test 
our hypothesis that CD11b is required for peripheral immune 
tolerance, we studied the role of CD11b in low-dose antigen-
induced oral tolerance, based on a commonly used feeding 
regimen (18). Thus, wild-type (WT) and CD11b−/− mice 
were fed with 1 mg OVA in PBS or PBS alone daily for 7 d, 
and then immunized with OVA emulsified in complete 
Freund’s adjuvant (CFA). 7 d later, OVA-specifi  c delayed-
type hypersensitivity (DTH) was determined. In both WT and 
CD11b−/− mice that received PBS only, immunization with 
OVA induced strong immune responses, as indicated by 
increment in footpad thickness upon challenge with particulate 
OVA (Fig. 1 a). Thus, CD11b defi  ciency does not aff  ect im-
mune activation. On the other hand, feeding WT mice with 
low-dose OVA strongly suppressed the subsequent immune 
response, as no signifi  cant footpad swelling developed in the 
fed WT mice. In contrast, similarly fed CD11b−/− mice still 
developed strong DTH responses (Fig. 1 a), demonstrating 
that CD11b−/− mice are defective in developing immune 
suppression upon low-dose antigen feeding.
The lack of immune suppression in CD11b−/− mice was 
directly verifi  ed by in vitro antigen-induced lymphocyte prolif-
eration assays. Single-cell suspensions prepared from the drain-
ing LNs of immunized mice with or without low-dose antigen 
feeding were restimulated in vitro with graded concentrations 
of OVA in 96-well plates for 72 h, and cell proliferation was 
measured on day 3 by [3H]thymidine incorporation. Lympho-
cytes from immunized WT and CD11b−/− mice showed simi-
larly strong antigen-dependent proliferation (Fig. 1 b), again 
demonstrating that CD11b defi  ciency does not adversely aff  ect 
antigen-specifi  c immune responses. Low-dose oral OVA ad-
ministration signifi  cantly suppressed the resultant proliferation 
of lymphocytes from WT mice, but did not aff  ect the prolifer-
ation of lymphocytes from similarly fed CD11b−/− mice (Fig. 
1 b). Together, these results revealed that unlike other known 
costimulatory molecules present on APCs, such as B7.1, B7.2, 
and ICOSL, which support both activation and suppression 
(4, 5, 19), CD11b/CD18 is uniquely involved in oral tolerance, 
but not in immune activation.
The defective immune tolerance in CD11b−/− mice can be 
restored by passive transfer of WT APCs
Professional APCs, which express high levels of CD11b, may 
depend on this molecule to support oral tolerance. In support 
of this hypothesis, adoptive transfer of total splenocytes or 
  adhesion-enriched APCs from naive WT mice into CD11b−/− 
mice, followed by antigen feeding, restored oral tolerance in 
CD11b−/− mice, as indicated by the substantial reduction in 
OVA-induced footpad swelling (Fig. 1 c), strongly arguing that 
Figure 1.  CD11b is required for induction of oral tolerance. 
(a) CD11b defi  ciency prevents orally induced peripheral tolerance as deter-
mined by DTH. WT C57BL/6 or CD11b−/− mice were fed daily with PBS or 
1 mg OVA for 7 d, and then immunized with OVA/CFA. After 7 d, these 
mice were challenged with OVA in the left footpad and saline in the right 
footpad. Footpad thickness was measured after 24 h, and the increase in 
thickness (swelling) between the left and right footpads is given. *, P = 
0.0015, WT versus CD11b−/−. n = 3–6. (b) CD11b defi  ciency prevents 
tolerance in OVA-stimulated lymphocyte proliferation. Total LN cells from 
the OVA-fed and immunized WT and CD11b−/− mice were stimulated with 
graded concentrations of OVA, and proliferation was measured after 72 h 
by [3H]thymidine incorporation. P = 0.00003, WT versus CD11b−/−. n = 4. 
(c) Restoration of oral tolerance in CD11b−/− mice by passive transfer of 
WT APCs. CD11b−/− mice were injected i.v. with splenocytes or adhesion-
enriched APCs from naive WT mice, and then fed with PBS or 1 mg OVA 
per day for 7 d. Establishment of oral tolerance in recipient CD11b−/− 
mice is determined by DTH response to OVA. *, P = 0.04, PBS versus OVA. 
n = 3. Data shown are means ± the SEM and are representative of three 
to four independent experiments.JEM VOL. 204, July 9, 2007  1521
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CD11b expressed on APCs is likely involved in the process of 
oral tolerance in OVA-fed mice.
Given a potential role of CD11b/CD18 in leukocyte traf-
fi  cking, CD11b defi  ciency may change the cellular composition 
of the lymphoid organs in response to antigen feeding, thus 
abolishing oral tolerance. However, no signifi  cant diff  erences in 
either the percentage or the total number of CD19+ (B cells), 
CD3+ (T cells), and MHC-II+ (APC) cells within the draining 
mesenteric LNs (mLNs) were observed between OVA-fed WT 
and CD11b−/− mice (Table S1, available at http://www.jem
.org/cgi/content/full/jem.20062292/DC1). CD11b defi  ciency 
may also interfere with DC maturation within the draining LNs 
in response to antigen feeding, which is very unlikely given the 
normal immune response observed in Fig. 1 a. Indeed, two-
color fl  ow cytometric analysis of the DC population within the 
draining mLN cells, using CD11c as a marker, showed similar 
surface expression of MHC-II, CD40, and CD86 between 
OVA-fed WT or CD11b−/− mice (Fig. S1).
CD11b defi  ciency promotes Th17 immune deviation under 
the oral tolerance condition
To understand the cellular mechanism by which CD11b 
  defi  ciency abolished the establishment of oral tolerance, we 
analyzed cytokine production by draining LN cells in response 
to antigen restimulation. Single-cell suspension was prepared 
from the inguinal LNs (iLNs) of PBS- or OVA-fed and im-
munized WT and CD11b−/− mice and restimulated with OVA 
for 3 d, and their supernatants were analyzed for cytokine 
production using multiplex microbead-based cytokine assay 
kit. Compared with naive mice (not depicted), immunization 
increased the production of IL-2 and -6 similarly in WT and 
CD11b−/− mice (Fig. 2 a). Under antigen-feeding condi-
tions, CD11b−/− mice exhibited approximately sixfold in-
creased cytokine production when compared with similarly 
fed WT mice (P < 0.001). Production of IL-17 was only 
observed in CD11b−/− mice.
A major source of IL-17 expression has been attributed to 
a newly described Th17 cell population (20, 21). Thus, the 
presence of large quantities of IL-17 suggested that CD11b 
defi  ciency may result in Th17 immune deviation in vivo. In 
support of this hypothesis, IL-6, which is another cytokine 
that is associated with the development of Th17 cells (9, 10), 
was also detected in large quantities in the supernatants from 
antigen-fed and immunized CD11b−/− mice (Fig. 2 a). To di-
rectly test our hypothesis, we examined whether CD11b−/− 
mice contained a Th17 cell population under the condition of 
oral tolerance induction. Thus, single-cell suspension was 
obtained from the draining iLNs of PBS- or OVA-fed and 
immunized WT or CD11b−/− mice, and the presence of  Th 17 
cells within CD4+ population, as characterized by expression 
of IL-17, but not IFNγ, was determined by intracellular stain-
ing with their corresponding antibodies according to an es-
tablished protocol (20, 21). Indeed, fl  ow cytometric analyses 
revealed fi  vefold more IL-17+IFNγ– cells within the gated 
CD4+ cells (i.e., Th17 cells) obtained from OVA-fed CD11b−/− 
mice than that from OVA-fed WT mice (Fig. 2 b). Statistical 
analysis showed a signifi  cant increase in the percentage of 
Th17 cells within the draining LNs of CD11b−/− mice com-
pared with WT mice (P = 0.0001; n = 12; Fig. 2 c). No de-
tectable Th17 population was observed in either naive WT or 
CD11b−/− mice (unpublished data).
To verify if the IL-17–expressing T cells represented a ma-
ture and stable Th17 population, we tested whether they could 
respond to restimulation by TGFβ, which is a cytokine that 
promotes the diff  erentiation of Th17 cells (9, 10), and by IL-23, 
which is a cytokine that promotes their proliferation (9, 22). 
Thus, total CD4+ T cells were isolated from OVA-fed and im-
munized WT and CD11b−/− mice, and then restimulated with 
Figure 2.  CD11b defi  ciency leads to Th17 immune deviation under 
the condition of oral tolerance induction. (a) Cytokine production in 
response to antigen restimulation. Singe-cell suspension, obtained from 
the iLNs of PBS- or OVA-fed and immunized WT (open bar) or CD11b−/− 
(shaded bar) mice, were restimulated in vitro with 100 μg/ml OVA for 72 h, 
and the cytokine concentrations in the supernatants were determined 
by microbead multiplex assay. *, P < 0.001, WT versus CD11b−/−. n = 4. 
(b) Identifi  cation of Th17 cells by intracellular staining. Total CD4+ T cells 
obtained from PBS- or OVA-fed and immunized mice were stimulated 
with PMA and ionomycin in the presence of GolgiPlug for 5 h, and then 
analyzed for intracellular expression of IL-17 and IFNγ by three-color 
fl  ow cytometry. Plots were gated on CD4+ cells (top, gate R3) and the 
percentages of cells staining positive for IL-17 or IFNγ were shown. 
(c) Existence of a Th17 cell population in CD11b−/− mice under conditions 
of oral tolerance induction. The percentages of Th17 cells, identifi  ed by their 
production of IL-17, but not IFNγ, within CD4+ subpopulation (gate R3), 
were determined by fl  ow cytometry. Data shown are the means ± the SEM 
and are representative of three independent experiments. *, P = 0.0001, 
WT versus CD11b−/−. n = 12.1522  CD11B ON APC IS CRITICAL TO PERIPHERAL TOLERANCE | Ehirchiou et al. 
TGFβ or IL-23 for 3 d in the presence of their corresponding 
irradiated APCs and anti-CD3. Only CD4+ T cells derived 
from CD11b−/− mice, but not from WT mice, responded vig-
orously to either TGFβ or IL-23 treatment (Fig. 3 a). When 
subjected to diff  erent T cell–polarizing conditions, CD4+ 
T cells isolated from CD11b−/− mice responded vigorously to 
restimulation by TGFβ plus IL-6 (Th17 polarizing), such that 
the Th17 population expanded from 13% (basal level; Fig. 2 b) 
to 44%. In contrast, no signifi  cant expansion of Th17 cells was 
observed when they were restimulated with IFNγ plus anti–IL-4 
(Th1 polarizing) or with IL-4 plus anti-IFNγ (Th2 polarizing). 
In agreement with recent reports (9, 22), a small population of 
CD4+ T cells (most likely the naive population) from WT 
mice also responded to the Th17 polarizing condition, and dif-
ferentiated to Th17 cells (18% for WT vs. 44% for CD11b−/−). 
Interestingly, although Th17 cells did not respond to the Th2 
polarizing condition, restimulation with IL-4 plus anti-IFNγ 
led to a small population (7–14%) of IFNγ-expressing cells for 
both WT and CD11b−/− cells (Fig. 3 b).
Suppression of IL-17 production by CD11b is critical 
to the development of oral tolerance
To test our hypothesis, we evaluated whether administration 
of exogenous IL-17 could block the establishment of oral 
tolerance in WT mice. Thus, WT mice were injected i.v. with 
IL-17 (60 pg/mouse/d) and simultaneously fed with low-dose 
OVA for 7 d. The development of OVA-specifi  c immune 
tolerance was assessed by the DTH response, as described in 
Fig. 1 a. Low-dose IL-17 injections did not signifi  cantly aff  ect 
the total blood leukocyte counts (unpublished data), but com-
pletely abrogated OVA-specifi  c immune tolerance, leading to 
the development of OVA-specifi  c DTH response in WT mice, 
when compared with the PBS-injected and antigen-fed WT 
control mice (Fig. 4). Based on the above results, we propose 
that genetic inactivation of CD11b leads to enhanced produc-
tion of IL-6 by APCs, which, in the presence of TGF-β, pro-
mote Th17 immune deviation (9, 10). The presence of Th17 
cells and their production of IL-17 within the draining LNs 
interfere with oral tolerance in CD11b−/− mice.
Th17 cells and the cytokine IL-17 they produce are asso-
ciated with a variety of allergic and autoimmune diseases, in-
cluding rheumatoid arthritis, multiple sclerosis, infl  ammatory 
bowel disease, and asthma (23-26). Our observation that skewed 
diff  erentiation toward Th17 pathway in CD11b−/− mice 
blocks the establishment of oral tolerance is consistent with 
these clinical observations. Thus, the information provided from 
this study not only helps us better understand the function of 
APCs in oral tolerance but also may have clinical implications 
for patients with autoimmune diseases.
MATERIALS AND METHODS
Mice. WT and CD11b−/− strains were all in the C57BL/6J background, used 
at 8–13 wk old. WT mice were purchased from the National Cancer Institute; 
CD11b−/− mice were provided by C.M. Ballantyne (Baylor College of 
Medicine, Houston, TX) (27) and have been backcrossed to the C57BL/6J 
background for more than seven generations. Animals were housed in a 
pathogen-free facility, and all procedures were performed in accordance with 
the Institutional Animal Care and Use Committee approval.
Antibodies and reagents. FITC–anti–mouse CD4 (clone GK1.5) was pur-
chased from Miltenyi Biotec Inc. FITC–anti–mouse CD25 (clone 7D4), PE–
anti-CD3 (clone17A2), PerCP–anti-CD4 (clone L3T4), FITC–anti-CD86 
Figure 3.  Existence of a mature Th17 population in antigen-fed 
and immunized CD11b−/− mice. (a) The IL-17–expressing cells represent 
a mature and stable Th17 population. Total CD4+ T cells, which were puri-
fi  ed by MACS from the iLNs of OVA-fed and immunized WT or CD11b−/− 
mice, were cocultured with their corresponding irradiated APCs in the 
presence of anti-CD3 mAbs with or without 2 ng/ml TGFβ or 20 ng/ml 
IL-23 plus anti–IL-4 and anti-IFNγ for 3 d. They were then restimulated 
with PMA and ionomycin in the presence of GolgiPlug for 5 h to retain 
the cytokines intracellularly. The restimulated cells were analyzed by intra-
cellular staining with anti–IL-17 and anti-IFNγ, and the percentages of 
CD17+IFNγ– cells within CD4+ population were determined by three-
color fl  ow cytometry and shown on the right. *, P < 0.0001, WT versus 
CD11b−/−. n = 4. (b) Th17 cells from CD11b−/− mice are capable of main-
taining a stable Th17 phenotype under different polarizing conditions. 
Purifi  ed CD4+ T cells from OVA-fed and immunized WT or CD11b−/− mice 
were cocultured with their irradiated APCs in the presence of anti-CD3 
under either Th1 (IFNγ plus anti-IL-4), Th2 (IL-4 plus anti-IFNγ), or 
Th17 (TGFβ plus IL-6) polarizing conditions for 3 d. The percentage of 
CD17+IFNγ– CD4+ T cells was determined by intracellular cytokine staining. 
Data shown are representative of three mice per group; these experiments 
were repeated three times, with similar results.JEM VOL. 204, July 9, 2007  1523
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(clone 24F), FITC–anti-CD19 (clone 1D3), and FITC–anti-IFNγ (clone 
XMG1.2) were obtained from BD Biosciences. R-PE–anti–mouse IL-17 
(clone TC11-18H10.1) was purchased from BioLegend. Rat anti-CD11b 
(clone M1/70), FITC–anti-MHC-II (clone M5/114.15.2), and their res-
pective control IgGs were purchased from eBioscience. Hamster anti-CD3 
(clone 1452C11) was obtained from the American Type Culture Collection. 
Recombinant IL-17 was purchased from Biosource. IL-4 was obtained from 
Pierce Chemical Co., IL-6 and -23 were purchased from R&D Systems, and 
IFNγ was purchased from CHEMICON International, Inc.
Tolerance induction and determination of DTH. The method of 
Miller et al. was used for tolerance induction, with minor modifi  cations (18). 
In brief, low-dose oral tolerance was induced by feeding 1 mg OVA per day 
via drinking water for 7 d. In certain experiments, wild-type mice (5–6 mice 
per group) were injected i.v. daily with either IL-17 (60 pg/mouse) or PBS, 
while being fed with 1 mg OVA for 7 d. The extent of tolerance induced by 
these methods was measured by DTH in response to OVA immunization. 
Accordingly, mice were primed by injecting s.c. 200 μl OVA/CFA emul-
sion (100 μl of 250 μg OVA plus 100 μl CFA) at the tail base, and then 
challenged after 7 d with 50 μl of aggregated OVA (10 mg/ml) injected into 
the left footpad. The right footpad received 50 μl of saline serving as control. 
The thickness of both hind footpads was measured 24 and 48 h later with a 
caliper, and the thickness increment was calculated as the diff  erence between 
the left and right footpad measurements.
Adoptive cell transfer. Single-cell suspensions were prepared from spleens 
harvested from naive WT mice and allowed to adhere to tissue culture dishes 
in complete media (RPMI-1640, 10% FBS, 10 mM Hepes, 1 mM sodium 
pyruvate, 1× nonessential amino acids, 50 μM 2-mercaptoethanol, and 
penicillin (100 U/ml streptomycin [100 μg/ml]) at 37°C for 30 min, and the 
nonadherent cells were removed by washing. The adherent cells (i.e., adhesion-
enriched APCs) were detached mechanically without trypsin, which contained 
<5% contaminating T cells based on fl  ow cytometry. The WT splenocytes 
or APCs (2 × 106) were injected i.v. into the recipient CD11b−/− mice, 
which were then fed with 1 mg OVA daily for 7 d. Immune responses to 
OVA were assessed by DTH as indicated by OVA-induced footpad swelling, 
as described in the pervious section.
Cell proliferation and cytokine measurement. Single-cell suspensions 
were prepared from the iLNs of WT or CD11b−/− mice that were fed with 
PBS or OVA and primed with OVA. Cells (5 × 105 cells/well) were cultured 
in 200 μl/well of RPMI-1640 plus 5% FBS at 37°C and 5% CO2 in 96-well 
fl  at-bottom culture plates in the presence of graded concentrations of OVA 
(0–1,000 μg/ml). Cell proliferation was measured after 3 d by [3H]thymidine 
incorporation. In brief, [3H]thymidine (1 μCi/well; PerkinElmer) was 
added during the last 16 h of incubation, cells were harvested onto glass-fi  ber 
fi  lters (Millipore), and [3H]thymidine incorporation was measured by liquid 
scintillation. Results are reported as the mean ± the SEM of triplicate or 
quadruplicate wells per group, and they are representative of two to four 
independent experiments. For cytokine determination, cultured super-
natants were collected after 72 h, and cytokine concentrations were mea-
sured by Luminex fl  uorescent bead–based multiplex cytokine assay system 
using the BioPlex program (Bio-Rad Laboratories) according to the manu-
facturer’s instructions.
In vitro diff  erentiation/expansion of Th17 cells. Total CD4+ T cells 
were prepared using CD4+ T cell isolation kit (Miltenyi Biotec) from the 
iLNs of WT or CD11b−/− mice that were fed with OVA for 7 d and im-
munized with OVA/CFA at the tail base for 7 d. Isolated CD4+ T cells 
(105 cells/well) were cocultured with their corresponding irradiated APCs 
(3 × 105 cells/well; adhesion-enriched) in 200 μl/well of complete media plus 
10 μg/ml anti-CD3 (mAb 1452C11) and diff  erent sets of cytokines and anti-
bodies, as follows: 20 ng/ml IFNγ plus 10 μg/ml anti–IL-4 (for Th1 polar-
ization); 20 ng/ml IL-4 plus 10 μg/ml anti-IFNγ (for Th2 polarization); or 
2 ng/ml TGFβ plus 8 ng/ml IL-6 (for Th17 polarization) at 37°C for 3 d. 
Diff   erentiation/expansion of Th17 cells was determined by intracellular 
staining using anti–IL-17 and anti-IFNγ, and the Th17 cells were identifi  ed 
as IL-17+IFNγ– CD4+ cells by three-color fl  ow cytometry.
Intracellular cytokine staining. To retain the cytokines intracellularly, 
the cell mixtures obtained from the draining LNs of diff  erent mice or from 
the in intro cell cultures were restimulated with 50 ng/ml PMA and 2 μM 
ionophore in the presence of 1 μl GolgiPlug (BD Biosciences) in complete 
media at 37°C for 5 h. These cells were then incubated with Fc Blocker (clone 
2.4G2; BD Biosciences) at 4°C, stained with a fi  rst set of fl  uorescence-
  labeled (FITC, PE, or PerCP) antibodies for 25 min, and then washed and 
permeabilized with Cytofi  x/Cytoperm solution (BD Biosciences) for 20 min. 
These cells were then incubated with a second set of antibodies at 4°C for 
30 min, washed, and analyzed by two- or three-color fl  ow cytometry (FACScan; 
BD Biosciences) using CellQuest software (BD Biosciences).
Statistical analysis. Statistical analyses were performed using Student’s t test 
(Systat Software, Inc.). P values <0.05 were considered signifi  cant.
Online supplemental materials. Fig. S1 shows that CD11b defi  ciency 
did not compromise DC maturation in response to antigen feeding. Table S1 
shows that CD11b defi  ciency did not aff  ect leukocyte traffi   cking into the 
draining LNs. The online version of this article is available at http://www
.jem.org/cgi/content/full/jem.20062292/DC1.
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